Home » Stocks » ORMP

Oramed Pharmaceuticals Inc. (ORMP)

Stock Price: $15.98 USD 1.58 (10.97%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $16.01 +0.03 (0.19%) Jul 26, 7:20 PM
Market Cap 468.20M
Revenue (ttm) 2.70M
Net Income (ttm) -18.80M
Shares Out 29.93M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $15.98
Previous Close $14.40
Change ($) 1.58
Change (%) 10.97%
Day's Open 15.00
Day's Range 14.90 - 16.63
Day's Volume 2,074,166
52-Week Range 2.40 - 16.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced several updates for its majority-owned company Oravax Medical Inc. Oravax is gearing up to commence clinical trials for its oral COVID-19 vaccine, fir...

5 days ago - Benzinga

NEW YORK, June 22, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

1 month ago - PRNewsWire

NEW YORK, June 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

1 month ago - PRNewsWire

NEW YORK, May 25, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

2 months ago - PRNewsWire

NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

3 months ago - PRNewsWire

NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

4 months ago - PRNewsWire

GURUGRAM, India--(BUSINESS WIRE)-- #Antibodies--Premas Biotech and Oramed announce Oral COVID-19 vaccine candidate that produces Antibodies after a single dose.

4 months ago - Business Wire

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has entered into definitive agreements to form a joint venture focused on developing oral COVID-19 vaccines. The new company, Oravax Medical Inc, will use Orame...

4 months ago - Benzinga

NEW YORK, March 19, 2021 /PRNewswire/ -- Good candidate for protection against COVID variants due to triple antigen targeting  Implications for potential ease of widescale distribution and administratio...

4 months ago - PRNewsWire

NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery system...

4 months ago - PRNewsWire

NEW YORK, March 4, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

4 months ago - PRNewsWire

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

6 months ago - PRNewsWire

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

6 months ago - PRNewsWire

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

7 months ago - PRNewsWire

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

7 months ago - PRNewsWire

NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems...

8 months ago - PRNewsWire

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems...

8 months ago - PRNewsWire

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

8 months ago - PRNewsWire

NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

9 months ago - PRNewsWire

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

10 months ago - PRNewsWire

NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

10 months ago - PRNewsWire

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

10 months ago - PRNewsWire

Pharmaceutical companies have poured millions—maybe billions—of dollars into research aimed at finding a way to deliver insulin to patients by mouth.

1 year ago - GuruFocus

NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...

1 year ago - PRNewsWire

About ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a w... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Nadav Kidron
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ORMP
Full Company Profile

Financial Performance

In 2020, ORMP's revenue was $2.71 million, an increase of 0.26% compared to the previous year's $2.70 million. Losses were -$11.51 million, -19.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ORMP stock is "Strong Buy." The 12-month stock price forecast is 22.50, which is an increase of 40.80% from the latest price.

Price Target
$22.50
(40.80% upside)
Analyst Consensus: Strong Buy